MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clml.2024.09.007

Медицинская библиотека · Clinical lymphoma, myeloma & leukemia · 2024

Real World Outcome of High-Risk Multiple Myeloma: An Indian Tertiary Care Centre Experience.

Soni Anveshika, Rainchwar Sujay, Singh Reema, Gupta Dikshat Gopal, Tikare Nakul, Halder Rohan, Palatty Roy J, Sheth Vipul Sharad, Agrawal Narendra, Bhurani Dinesh, Panda Tribikram

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

High risk myeloma is heterogeneous with significant variation in risk stratifications. Real world outcomes differ from controlled clinical trials and affected by socioeconomical determinants.

MATERIAL AND

METHODS

This retrospective study was performed in a North Indian teriarty care cancer hospital. Out of 384,76(19.7%) high risk myeloma patients (median age 58 years) were analyzed.

RESULT AND

CONCLUSION

Most common HRCA was 1 q gain 36(47.4%) followed by del17p 32(42.1%). 61/76(80.2%) received bortezomib based triplets and 15(19.74%) daratumumab based quadruplets induction, 31(40.79%) received ASCT. Median duration of follow up was 19.5 months. The 2 year OS and PFS was 73.8%, 52.6% respectively. Estimated 3 year OS was 74.7% in ASCT cohort versus 52.9% (P = .0067) without. Estimated 3-year PFS in the ASCT cohort was 72.1% versus 30.3% (P = .0026) without. Estimated 3-year OS for single hit and multi hit ultra HRMM was 67.7% and 61.9% (P = .642) whereas PFS was 58.2% and 35.2% (P = .486) respectively. In multivariate analysis ASCT correlated with better OS (HR 0.3, P = .041) and PFS (HR 0.35, P = .012). Absence of baseline renal impairment correlated with better OS (HR 4.12, P = .004) only. Early aggressive therapy with prompt ASCT translates to a better survival in high risk myeloma. Emphasis on real world clinical outcome is the need of the hour for addressing practical issues and improving global myeloma outcome.

Для цитирования: Soni Anveshika, Rainchwar Sujay, Singh Reema, Gupta Dikshat Gopal, Tikare Nakul, Halder Rohan, Palatty Roy J, Sheth Vipul Sharad, Agrawal Narendra, Bhurani Dinesh, Panda Tribikram. Real World Outcome of High-Risk Multiple Myeloma: An Indian Tertiary Care Centre Experience.. Clinical lymphoma, myeloma & leukemia. 2024. DOI: 10.1016/j.clml.2024.09.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.